Determinants of hormone replacement therapy among postmenopausal women enrolled in the French GAZEL cohort
- PMID: 8148567
- DOI: 10.1007/BF02352256
Determinants of hormone replacement therapy among postmenopausal women enrolled in the French GAZEL cohort
Abstract
Although the efficacy of hormonal replacement therapy (HRT) regarding numerous consequences of menopause is proven, its prevalence of use is low, as is compliance with the prescribed treatment. The aim of this work was to study the factors influencing a woman's decision to take HRT by analyzing the determinants of HRT use of at least 6 months' duration among post-menopausal women working for a French company and enrolled in a cohort study. Special attention was paid to the women's expectations of HRT. We compared two groups of women: 113 current HRT users who had been users for at least 6 months and 101 never users. Among the 113 current users, the most frequent treatment was a combination of oestrogen and progestin (86%). The determinants of HRT use for at least 6 months included a prior spinal radiograph, which showed a significant relationship with the use of hormone treatment (odds ratio (OR) 2.4; 95% confidence interval (CI) 1.2-4.7), a current marriage (OR 2.5; 95% CI 1.3-5.1) and previous hot flushes (OR 2.4; 95% CI 1.2-4.9). The strongest determinant was an expectation that HRT would prevent osteoporosis (OR 5.0; 95% CI 2.2-11.6). In this population concern about osteoporosis appears to be an important determinant of HRT use. Our results underline the importance of the diffusion of information among physicians and women about HRT's benefits, especially its efficacy in preventing osteoporosis.
Similar articles
-
Postmenopausal hormone replacement therapy: scientific review.JAMA. 2002 Aug 21;288(7):872-81. doi: 10.1001/jama.288.7.872. JAMA. 2002. PMID: 12186605 Review.
-
Why do women doctors in the UK take hormone replacement therapy?J Epidemiol Community Health. 1997 Aug;51(4):373-7. doi: 10.1136/jech.51.4.373. J Epidemiol Community Health. 1997. PMID: 9328541 Free PMC article.
-
Prevalence and characteristics associated with use of hormone replacement therapy in Britain.Br J Obstet Gynaecol. 1997 Mar;104(3):290-7. doi: 10.1111/j.1471-0528.1997.tb11456.x. Br J Obstet Gynaecol. 1997. PMID: 9091004
-
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.Menopause. 2003 Sep-Oct;10(5):412-9. doi: 10.1097/01.GME.0000086467.82759.DA. Menopause. 2003. PMID: 14501602
-
Oestrogen replacement in postmenopausal women.Age Ageing. 2015 Jul;44(4):551-8. doi: 10.1093/ageing/afv069. Epub 2015 Jun 11. Age Ageing. 2015. PMID: 26070875 Review.
Cited by
-
Psychosocial factors at work and sickness absence in the Gazel cohort: a prospective study.Occup Environ Med. 1998 Nov;55(11):735-41. doi: 10.1136/oem.55.11.735. Occup Environ Med. 1998. PMID: 9924449 Free PMC article.
-
[Factors influencing the adoption of hormone replacement therapy].Can Fam Physician. 1998 Jun;44:1280-6. Can Fam Physician. 1998. PMID: 9640522 Free PMC article.
-
Educating patients about the benefits and drawbacks of hormone replacement therapy.Drugs Aging. 1998 Jul;13(1):33-41. doi: 10.2165/00002512-199813010-00004. Drugs Aging. 1998. PMID: 9679207 Review.
-
Estimated numbers of postmenopausal women treated by hormone therapy in France.Maturitas. 2005 Nov-Dec;52(3-4):296-305. doi: 10.1016/j.maturitas.2005.05.002. Epub 2005 Jun 13. Maturitas. 2005. PMID: 15955641 Free PMC article.
-
Symptomatic pelvic organ prolapse at midlife, quality of life, and risk factors.Obstet Gynecol. 2009 Mar;113(3):609-616. doi: 10.1097/AOG.0b013e3181985312. Obstet Gynecol. 2009. PMID: 19300324 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources